^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGFR4 (Fibroblast growth factor receptor 4)

    i
    Other names: FGFR4, CD334, JTK2, Fibroblast growth factor receptor 4
    3d
    Proteome-Wide Analysis of Functional Phosphosites in the FGFR Family of Proteins: Insights from Large-Scale Phosphoproteomic Analysis. (PubMed, Proteomes)
    Our findings highlight key disease-associated phosphosites within the FGFRs and offer a foundation for advancing phosphosite-focused therapeutic research.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • MAPK1 (Mitogen-activated protein kinase 1)
    4d
    Targeted therapy for liver cancer: Current status and future directions. (PubMed, Bioimpacts)
    By blocking the mechanisms that lead to angiogenesis and tumor growth, first-line systemic treatments, such the multi-tyrosine kinase inhibitors (TKIs) lenvatinib and sorafenib, have shown moderate improvements in survival. However, their long-term efficacy is significantly reduced by intrinsic and acquired resistance, which is why second-line medications like regorafenib, cabozantinib, and ramucirumab are being studied. When combined with anti-VEGF treatments, parallel developments in immunotherapy, in particular immune checkpoint inhibitors (ICIs) such as atezolizumab and nivolumab, have shown promising outcomes...In the end, the review promotes the combination of dynamic molecular profiling and biomarker-driven precision medicine to enhance patient stratification, improve treatment decision-making, and provide long-lasting clinical effects. A strategic foundation for future advancements and individualized treatment of hepatocellular carcinoma is provided by this comprehensive synthesis.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • FGFR4 (Fibroblast growth factor receptor 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • sorafenib • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Cyramza (ramucirumab)
    11d
    Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody. (PubMed, Cancers (Basel))
    This study successfully identified several CSC-selective membrane antigens that can become therapeutic targets in CRC. Among them, we focused on FGFR4 as a promising target and developed the anti-FGFR4 3B6 monoclonal antibody which offers potential for both diagnostic and therapeutic applications.
    Journal
    |
    FGFR4 (Fibroblast growth factor receptor 4)
    12d
    FGFR4 and HER2 co-expression is associated with the proinflammatory tumor microenvironment in HR + breast cancer. (PubMed, Breast Cancer)
    Co-expression of FGFR4 and HER2 is associated with a proinflammatory tumor microenvironment in HR+ breast cancer, suggesting immunotherapy potential. Further studies should explore therapeutic strategies to reshape the tumor immune microenvironment.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • LAG3 (Lymphocyte Activating 3) • FGFR4 (Fibroblast growth factor receptor 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • BTLA (B And T Lymphocyte Associated)
    |
    HER-2 positive • HR positive • HER-2 expression
    |
    AmoyDx® Master Panel
    13d
    Exploring the crosstalk between the FGF/FGFR pathway and tumor microenvironment in clear cell renal cell carcinoma. (PubMed, PLoS One)
    This study provides the first comprehensive evaluation of FGFR1-4 expression in ccRCC and suggests that FGFR1 expression may contribute to the immunosuppressive tumor microenvironment by recruiting TAM. These findings indicate that FGFR1 could serve as a potential biomarker for therapeutic strategies and highlight the need for further research to explore FGFR-targeted therapies in ccRCC.
    Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • IFNG (Interferon, gamma) • FGFR4 (Fibroblast growth factor receptor 4) • CD163 (CD163 Molecule) • GZMB (Granzyme B)
    |
    Keytruda (pembrolizumab) • sunitinib • Lenvima (lenvatinib)
    13d
    A validated UHPLC-MS/MS method for determination of BPI-43487 and its metabolite BPI-43739 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumors. (PubMed, Bioanalysis)
    This method was further successfully applied to a pharmacokinetic study of BPI-43487 capsules in Chinese patients with advanced solid tumors. http://www.chinadrugtrials.org.cn is CTR20210565).
    PK/PD data • Journal
    |
    FGFR4 (Fibroblast growth factor receptor 4)
    16d
    FGF19/FGFR4/KLB signaling participate in the ferroptosis regulation of hepatocellular carcinoma. (PubMed, Arab J Gastroenterol)
    In this research, results of western blotting and reactive oxygen species (ROS) assay demonstrated that knock down of KLB enhance the expression of TFRC, a driver gene of ferroptosis, thus blocking the ferroptosis inhibitory effect of FGF19. Based on these available evidence and data, we hypothesize that FGF19 signaling inhibit the ferroptotic cell death in HCC cells through FGFR4-KLB co-receptors, while suppression of FGFR4-KLB could block FGF19 signaling, thus trigger ferroptosis process.
    Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • KLB (Klotho Beta)
    20d
    Interventional effects of mesenchymal stem cells on epithelial-mesenchymal transition in head and neck squamous cell carcinoma and underlying mechanisms: a systematic review and meta-analysis of in vitro studies. (PubMed, Front Immunol)
    The existing in vitro evidence suggests that mesenchymal stem cells may exhibit a potential to promote EMT in HNSCC, potentially regulating tumor progression through multiple signaling pathway networks and providing new potential targets for future therapies targeting the TME. However, more high-quality, standardized in vivo and in vitro studies are needed to further validate the related mechanisms and therapeutic potential.
    Clinical • Preclinical • Retrospective data • Review • Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • IL6R (Interleukin 6 receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    24d
    Harnessing AACR Project GENIE to Define the Molecular Features of Desmoplastic Small Round Cell Tumor. (PubMed, Curr Issues Mol Biol)
    Our data highlights mutational variation across demographic cohorts. These patterns are vital to future studies into identifying diagnostic markers or therapeutic targets.
    Journal
    |
    TP53 (Tumor protein P53) • ARID1A (AT-rich interaction domain 1A) • FGFR4 (Fibroblast growth factor receptor 4) • KMT2C (Lysine Methyltransferase 2C) • WT1 (WT1 Transcription Factor) • EP300 (E1A binding protein p300) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • ANKRD1 (Ankyrin Repeat Domain 1) • TRAF1 (TNF Receptor Associated Factor 1) • PCLO (Piccolo Presynaptic Cytomatrix Protein)
    |
    TP53 mutation • ATM mutation • ARID1A mutation
    27d
    Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)
    Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 negative • HER-2 expression
    |
    tamoxifen • letrozole • anastrozole
    1m
    Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020-2025). (PubMed, Int Immunopharmacol)
    Their abnormal intracellular expression is a significant cause of tumorigenesis, making FGFRs key therapeutic targets in cancer treatment. This paper primarily summarizes the latest research advances in FGFR inhibitors, aiming to provide insights for future design and synthesis studies of FGFR inhibitors.
    Review • Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
    1m
    Novel FGFR4-Targeting Peptide for Single-Photon Emission Computed Tomography Imaging in Hepatocellular Carcinoma. (PubMed, J Med Chem)
    In this study, we designed a series of FGFR4-targeted peptide-radionuclide conjugates (PRCs) based on a high-affinity peptide ligand derived from the binding epitope of the monoclonal antibody U3-1784...In xenograft models, this probe demonstrated high uptake (1.89 ± 0.35% ID/g) and produced high-contrast images specifically in high-FGFR4-expressing tumors. These results indicate that 99mTc-HYNIC-FYQ-8 is a promising peptide-based radiotracer for clinical imaging of FGFR4-overexpressing tumors.
    Journal
    |
    FGFR4 (Fibroblast growth factor receptor 4)
    |
    U3-1784